Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.64 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.57 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22455074 | 1.00 | NCF1 (0.64) | NCF1EHMT2EHMT1ALDH1A1HTT | |
| SCHEMBL30337987 | 0.84 | NCF1 (0.65) | NCF1ALDH1A1HTTGAA | |
| SCHEMBL31457629 | 0.80 | NCF1 (0.75) | NCF1EHMT2EHMT1ALDH1A1NPC1 | |
| SCHEMBL22455396 | 0.79 | NCF1 (0.68) | NCF1EHMT2EHMT1NPC1PDGFRB | |
| SCHEMBL29357443 | 0.79 | NCF1 (0.68) | NCF1EHMT2EHMT1NPC1PDGFRB | |
| SCHEMBL22441572 | 0.78 | NCF1 (1.00) | NCF1EHMT2EHMT1ALDH1A1NPC1 | |
| SCHEMBL22455216 | 0.78 | NCF1 (0.71) | NCF1EHMT2EHMT1NPC1PDGFRB | |
| SCHEMBL27339050 | 0.78 | NCF1 (0.71) | NCF1EHMT2EHMT1ALDH1A1NPC1 | |
| SCHEMBL27140378 | 0.78 | ALDH1A1 (0.52) | NCF1ALDH1A1HTTPDGFRBPDE10A | |
| SCHEMBL24009160 | 0.78 | NCF1 (0.70) | NCF1EHMT2EHMT1NPC1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | NCF1 283/4885EHMT2 2342/4885EHMT1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.